AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36079790 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAAs (6 g BCAAs, 3 g leucine)
Number of subjects: 12
Study 36079790 — intervention group
Group type: COMPARATOR
Intervention: CHO placebo
Number of subjects: 12
Study 36079790 — intervention group
Group type: COMPARATOR
Intervention: REST and CHO placebo
Number of subjects: 12
Study 33638810 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin for ≥ 3 years with tamoxifen
Number of subjects: 222
Study 33638810 — intervention group
Group type: COMPARATOR
Intervention: Leuprorelin for 2 years with tamoxifen
Number of subjects: 222
Study 33638810 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin for ≥ 3 years with tamoxifen in higher-risk subgroup (n = 17)
Number of subjects: 222
Study 33638810 — intervention group
Group type: COMPARATOR
Intervention: Leuprorelin for 2 years with tamoxifen in higher-risk subgroup (n = 17)
Number of subjects: 222
Study 33638810 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (≥ 3 years and 2 years)
Number of subjects: 222
Study 36170006 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month caloric restriction
Number of subjects: 50
Study 36170006 — intervention group
Group type: COMPARATOR
Intervention: Active waiting group
Number of subjects: 50
Study 34585700 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 g of PEITC-rich vegetable sauce
Number of subjects: 21
Study 34585700 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g of PEITC-rich vegetable sauce
Number of subjects: 21
Study 34585700 — intervention group
Group type: COMPARATOR
Intervention: 100 g of placebo sauce
Number of subjects: 21
Study 36458325 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg daily with amoxicillin 1000 mg, furazolidone 100 mg, and colloidal bismuth 200 mg each given twice a day for 10 days (V10)
Number of subjects: 234
Study 36458325 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 20 mg daily with amoxicillin 1000 mg, furazolidone 100 mg, and colloidal bismuth 200 mg each given twice a day for 14 days (V14)
Number of subjects: 234
Study 36458325 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 20 mg with amoxicillin 1000 mg, furazolidone 100 mg, and colloidal bismuth 200 mg each given twice a day for 14 days (E14)
Number of subjects: 234
Study 32516805 — intervention group
Group type: EXPERIMENTAL
Intervention: GRACE 2.0 score for type 1 myocardial infarction
Number of subjects: 70271
Study 32516805 — intervention group
Group type: EXPERIMENTAL
Intervention: GRACE 2.0 score for type 2 myocardial infarction
Number of subjects: 70271
Study 32475048 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 42
Study 32475048 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 42
Study 35986979 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-first clinical decision support (CDS) tool
Number of subjects: 254
Study 35986979 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 254
Study 34338146 — intervention group
Group type: EXPERIMENTAL
Intervention: miR‐101‐3p mimic group
Number of subjects: 75
Study 34338146 — intervention group
Group type: EXPERIMENTAL
Intervention: CUL4B siRNA group
Number of subjects: 75
Study 34338146 — intervention group
Group type: EXPERIMENTAL
Intervention: CUL4B siRNA plus miR‐101‐3p inhibitor group
Number of subjects: 75
Study 34338146 — intervention group
Group type: COMPARATOR
Intervention: siRNA negative control (NC) group
Number of subjects: 75
Study 34338146 — intervention group
Group type: COMPARATOR
Intervention: Blank group
Number of subjects: 75
Study 34817421 — intervention group
Group type: EXPERIMENTAL
Intervention: Noradrenaline 5 μg min-1
Number of subjects: 0
Study 34817421 — intervention group
Group type: COMPARATOR
Intervention: Phenylephrine 100 μg min-1
Number of subjects: 0
Study 34453521 — intervention group
Group type: EXPERIMENTAL
Intervention: World Health Organization class III obesity (BMI > 40 kg/m2)
Number of subjects: 103
Study 34453521 — intervention group
Group type: COMPARATOR
Intervention: Less severe obesity (BMI 35 ± 5 kg/m2) during dobutamine
Number of subjects: 103
Study 34453521 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical weight loss (n = 37)
Number of subjects: 103
Study 34237154 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE plus lenvatinib (12 mg orally once daily for body weight ≥60 kg or 8 mg for body weight <60 kg)
Number of subjects: 64
Study 34237154 — intervention group
Group type: COMPARATOR
Intervention: TACE plus sorafenib (400 mg orally twice daily in 28-day cycles)
Number of subjects: 64
Study 32125668 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps tendon autograft (QTB)
Number of subjects: 100
Study 32125668 — intervention group
Group type: EXPERIMENTAL
Intervention: Semitendinosus-gracilis autograft (StG)
Number of subjects: 100
Study 32125668 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (CON)
Number of subjects: 100
Study 32125668 — intervention group
Group type: EXPERIMENTAL
Intervention: Both QTB and StG
Number of subjects: 100
Study 35597733 — intervention group
Group type: EXPERIMENTAL
Intervention: taVNS
Number of subjects: 8
Study 35597733 — intervention group
Group type: COMPARATOR
Intervention: CS
Number of subjects: 8
Study 35666260 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist guided game‐based intervention program (TGGIP)
Number of subjects: 138
Study 35666260 — intervention group
Group type: COMPARATOR
Intervention: Self‐oriented, nonsupervised program (GIP)
Number of subjects: 138
Study 34443994 — intervention group
Group type: EXPERIMENTAL
Intervention: Live music therapy applied during sleep
Number of subjects: 20
Study 34443994 — intervention group
Group type: EXPERIMENTAL
Intervention: Live music therapy applied in awake state
Number of subjects: 20
Study 34443994 — intervention group
Group type: EXPERIMENTAL
Intervention: Live music therapy (general)
Number of subjects: 20
Study 32636279 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 PEEP baseline SpO2
Number of subjects: 38
Study 32636279 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 PEEP + 0.20
Number of subjects: 38
Study 36194395 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 30
Study 36194395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 32668005 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT-enhanced integrated care model (SPEC)
Number of subjects: 482
Study 32668005 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 482
Study 32401099 — intervention group
Group type: EXPERIMENTAL
Intervention: FearFighter ICBT program (n = 32)
Number of subjects: 64
Study 32401099 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 32)
Number of subjects: 64
Study 33843267 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 104
Study 33843267 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 104
Study 33051228 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg ×2 daily for 7 days followed by vaginal Lactobacillus crispatus CTV‐05 until clinical pregnancy scan week 7‐9
Number of subjects: 333
Study 33051228 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin and placebo L. crispatus CTV‐05
Number of subjects: 333
Study 33051228 — intervention group
Group type: COMPARATOR
Intervention: Placebo/placebo
Number of subjects: 333
Study 34633260 — intervention group
Group type: EXPERIMENTAL
Intervention: S086 (single ascending doses: 60-1080 mg)
Number of subjects: 113
Study 34633260 — intervention group
Group type: EXPERIMENTAL
Intervention: S086 (multiple ascending doses: 180-720 mg)
Number of subjects: 113
Study 34633260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 33410497 — intervention group
Group type: EXPERIMENTAL
Intervention: Indicated prevention strategy (IPS) in RCT I
Number of subjects: 402
Study 33410497 — intervention group
Group type: EXPERIMENTAL
Intervention: Indicated prevention strategy (IPS) in RCT II
Number of subjects: 402
Study 33410497 — intervention group
Group type: COMPARATOR
Intervention: Control group in RCT I
Number of subjects: 402
Study 33410497 — intervention group
Group type: COMPARATOR
Intervention: Control group in RCT II
Number of subjects: 402
Study 33511399 — intervention group
Group type: EXPERIMENTAL
Intervention: Flannel drag fabric
Number of subjects: 0
Study 33511399 — intervention group
Group type: COMPARATOR
Intervention: Canvas drag fabric
Number of subjects: 0
Study 33511399 — intervention group
Group type: COMPARATOR
Intervention: Corduroy drag fabric
Number of subjects: 0
Study 36214066 — intervention group
Group type: EXPERIMENTAL
Intervention: ANTICIPATE models
Number of subjects: 222
Study 36214066 — intervention group
Group type: EXPERIMENTAL
Intervention: FIB4+ model (using FIB-4 plus serum albumin)
Number of subjects: 222
Study 33952540 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based consultation involving patient, general practitioner (GP), and oncologist
Number of subjects: 9
Study 33349906 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes SPECIAL elective
Number of subjects: 10
Study 33167705 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-month dual antiplatelet therapy (DAPT) followed by single antiplatelet therapy
Number of subjects: 1506
Study 33167705 — intervention group
Group type: COMPARATOR
Intervention: Single antiplatelet therapy
Number of subjects: 1506
Study 33453399 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 1930728
Study 33453399 — intervention group
Group type: COMPARATOR
Intervention: No PPI use
Number of subjects: 1930728
Study 33812945 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS to the left dlPFC (1 mA for 20 min)
Number of subjects: 40
Study 33812945 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS to the left dlPFC
Number of subjects: 40
Study 33812945 — intervention group
Group type: COMPARATOR
Intervention: Control condition (sham tDCS)
Number of subjects: 40
Study 34011557 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day)
Number of subjects: 364
Study 34011557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 364
Study 35649167 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan-bupropion (45 mg-105 mg tablet), orally (once daily for days 1-3, twice daily thereafter) for 6 weeks
Number of subjects: 327
Study 35649167 — intervention group
Group type: COMPARATOR
Intervention: Placebo, orally (once daily for days 1-3, twice daily thereafter) for 6 weeks
Number of subjects: 327
Study 35649167 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan-bupropion
Number of subjects: 327
Study 35649167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study 34500216 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl aminolevulinate photodynamic therapy (MAL‐PDT) with two treatments
Number of subjects: 33
Study 34500216 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl aminolevulinate photodynamic therapy (MAL‐PDT) with four treatments
Number of subjects: 33
Study 34500216 — intervention group
Group type: COMPARATOR
Intervention: Placebo vehicle (control)
Number of subjects: 33
Study 34524919 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 43
Study 34524919 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study 34988703 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary/interval debulking surgeries with classical chemotherapy (adjuvant/neoadjuvant) of intravenous tri‐weekly doses of paclitaxel + carboplatin
Number of subjects: 0
Study 34988703 — intervention group
Group type: EXPERIMENTAL
Intervention: Common toxicities (anemia, constipation, weight loss)
Number of subjects: 0
Study 33530190 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Number of subjects: 0
Study 33530190 — intervention group
Group type: COMPARATOR
Intervention: Sling treatment
Number of subjects: 0
Study 35102424 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg THC
Number of subjects: 40
Study 35102424 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg THC
Number of subjects: 40
Study 35102424 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (both doses)
Number of subjects: 40
Study 35102424 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 40
Study 34496848 — intervention group
Group type: EXPERIMENTAL
Intervention: Boosted darunavir plus dolutegravir (2DR)
Number of subjects: 263
Study 34496848 — intervention group
Group type: COMPARATOR
Intervention: Continuous boosted darunavir plus 2 nucleoside/nucleotide reverse‐transcriptase inhibitors (3DR)
Number of subjects: 263
Study 32084245 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology taping (KT)
Number of subjects: 45
Study 32084245 — intervention group
Group type: COMPARATOR
Intervention: Standard taping (ST)
Number of subjects: 45
Study 32084245 — intervention group
Group type: COMPARATOR
Intervention: No taping (NT)
Number of subjects: 45
Study 36128262 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg Olanzapine
Number of subjects: 210
Study 36128262 — intervention group
Group type: COMPARATOR
Intervention: Aprepitant
Number of subjects: 210
Study 32557475 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led educational intervention by telephone within 48 hours before colonoscopy
Number of subjects: 657
Study 32557475 — intervention group
Group type: COMPARATOR
Intervention: Standard bowel preparation protocol (Control)
Number of subjects: 657
Study 32557475 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led educational intervention by telephone (Per-protocol analysis)
Number of subjects: 657
Study 32557475 — intervention group
Group type: COMPARATOR
Intervention: Standard bowel preparation protocol (Control, Per-protocol analysis)
Number of subjects: 657
Study 36223406 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 wk pulmonary rehabilitation (PR) + routine medication
Number of subjects: 50
Study 36223406 — intervention group
Group type: COMPARATOR
Intervention: Routine medication (Control Group)
Number of subjects: 50
Study 36223406 — intervention group
Group type: EXPERIMENTAL
Intervention: EOS ≥ 200 cells/μL group (within RG)
Number of subjects: 50
Study 36223406 — intervention group
Group type: EXPERIMENTAL
Intervention: EOS < 200 cells/μL group (within RG)
Number of subjects: 50
Study 33494027 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided intrauterine insemination (UG-IUI)
Number of subjects: 320
Study 33494027 — intervention group
Group type: COMPARATOR
Intervention: Classical intrauterine insemination (C-IUI)
Number of subjects: 320
Study 33494027 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided intrauterine insemination (UG-IUI) for multigravida women
Number of subjects: 320
Study 33494027 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided intrauterine insemination (UG-IUI) for nulligravida women
Number of subjects: 320
Study 36345569 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Ring (DVR)
Number of subjects: 142
Study 36345569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 33340727 — intervention group
Group type: EXPERIMENTAL
Intervention: ESP-PCA
Number of subjects: 80
Study 33340727 — intervention group
Group type: COMPARATOR
Intervention: PCA
Number of subjects: 80
Study 35708823 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex intervention
Number of subjects: 0
Study 33827496 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Intervention - Standard Care (EI-SC) group, 30-day EI program
Number of subjects: 73
Study 33827496 — intervention group
Group type: COMPARATOR
Intervention: Standard Care - Early Intervention (SC-EI) group, standard care followed by EI in open phase
Number of subjects: 73
Study 33827496 — intervention group
Group type: COMPARATOR
Intervention: Reference group (retrospective)
Number of subjects: 73
Study 32792403 — intervention group
Group type: EXPERIMENTAL
Intervention: All-Christian soccer team
Number of subjects: 0
Study 32792403 — intervention group
Group type: COMPARATOR
Intervention: Mixed team with Muslims
Number of subjects: 0
Study 34049519 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg daily from 2 days pre-operation to 14 days post-surgery
Number of subjects: 96
Study 34049519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 32259902 — intervention group
Group type: EXPERIMENTAL
Intervention: Guideline-directed medical therapy (GDMT) for systolic heart failure, including renin angiotensin aldosterone system inhibitors, initiated at low doses with close monitoring of kidney function.
Number of subjects: 0
Study 32259902 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration for volume status management.
Number of subjects: 0
Study 32259902 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education and engagement regarding sodium and fluid restriction.
Number of subjects: 0
Study 37428421 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Intake Feedback (Alc)
Number of subjects: 436
Study 37428421 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Intake plus Cognitive Feedback (AlcCog)
Number of subjects: 436
Study 37428421 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 436
Study 33894037 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined 1-unit higher log-transformed serum MMP-8 concentration
Number of subjects: 6049
Study 32956804 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopedic RCTs
Number of subjects: 68
Study 32956804 — intervention group
Group type: COMPARATOR
Intervention: Non-orthopedic RCTs
Number of subjects: 68
Study 32956804 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopedic RCTs favoring non-operative management
Number of subjects: 68
Study 35803945 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology Supported BB intervention group
Number of subjects: 70
Study 35803945 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 32909316 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid for 28 weeks during pregnancy
Number of subjects: 847
Study 32909316 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 847
Study 32909316 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid
Number of subjects: 847
Study 32909316 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid and Efavirenz
Number of subjects: 847
Study 32909316 — intervention group
Group type: EXPERIMENTAL
Intervention: NAT2 and CYP2B6 genotypes
Number of subjects: 847
Study 33484485 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave ablation (MWA) followed by drug therapy
Number of subjects: 27
Study 33484485 — intervention group
Group type: COMPARATOR
Intervention: Control group (drug therapy only)
Number of subjects: 27
Study 32519221 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional adhesive patches (RockaDex, New Zealand)
Number of subjects: 34
Study 32519221 — intervention group
Group type: COMPARATOR
Intervention: Standard adhesive (control)
Number of subjects: 34
Study 32519221 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive patch use
Number of subjects: 34
Study 32519221 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive patch non-use
Number of subjects: 34
Study 35065080 — intervention group
Group type: EXPERIMENTAL
Intervention: C12 + TRP
Number of subjects: 12
Study 35065080 — intervention group
Group type: EXPERIMENTAL
Intervention: C12
Number of subjects: 12
Study 35065080 — intervention group
Group type: EXPERIMENTAL
Intervention: TRP
Number of subjects: 12
Study 35065080 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 12
Study 33030742 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (10 µg/day)
Number of subjects: 225
Study 33030742 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D insufficiency
Number of subjects: 225
Study 33030742 — intervention group
Group type: EXPERIMENTAL
Intervention: First-trimester vitamin D insufficiency
Number of subjects: 225
Study 33030742 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 225
Study 32600295 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately sequential bilateral cataract surgery (ISBCS)
Number of subjects: 0
Study 32600295 — intervention group
Group type: COMPARATOR
Intervention: Delayed sequential bilateral cataract surgery (DSBCS)
Number of subjects: 0
Study 32600295 — intervention group
Group type: EXPERIMENTAL
Intervention: ISBCS
Number of subjects: 0
Study 36235746 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg D-Pinitol (n = 10)
Number of subjects: 35
Study 36235746 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg D-Pinitol (n = 6)
Number of subjects: 35
Study 36235746 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 mg D-Pinitol from carob pods-derived syrup (n = 9)
Number of subjects: 35
Study 36235746 — intervention group
Group type: EXPERIMENTAL
Intervention: D-Pinitol (various doses)
Number of subjects: 35
Study 32668455 — intervention group
Group type: EXPERIMENTAL
Intervention: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF)
Number of subjects: 567
Study 32668455 — intervention group
Group type: COMPARATOR
Intervention: Dolutegravir/Emtricitabine/Tenofovir Alafenamide (DTG + F/TAF)
Number of subjects: 567
Study 32998938 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 4401
Study 32998938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4401
Study 35175380 — intervention group
Group type: EXPERIMENTAL
Intervention: CCTA
Number of subjects: 1133
Study 35175380 — intervention group
Group type: COMPARATOR
Intervention: FFRCT
Number of subjects: 1133
Study 35987552 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session online cognitive bias modification (CBM-IA) targeting interpretation bias and attribution style.
Number of subjects: 45
Study 35987552 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified).
Number of subjects: 45
Study 32430879 — intervention group
Group type: EXPERIMENTAL
Intervention: SNAPPS
Number of subjects: 60
Study 32430879 — intervention group
Group type: COMPARATOR
Intervention: OMP
Number of subjects: 60
Study 33454705 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training
Number of subjects: 66
Study 33454705 — intervention group
Group type: EXPERIMENTAL
Intervention: Training on healthy volunteer
Number of subjects: 66